Table 2.
Results of a main-effect multivariate Cox proportional hazards regression model with pre-treatment total MTV (tMTV-pre) as a continuous covariate, along with potential confounders, to predict overall survival (OS).
| Parameter | Estimate (SE) |
Hazard ratio (95% CI) |
P-value |
|---|---|---|---|
| Age (years): continuous | 0.019 (0.010) | 1.02 (1.00, 1.04) | 0.053 |
| Gender: female (vs. male) | 0.091 (0.176) | 1.10 (0.78, 1.55) | 0.607 |
| Baseline performance status: ambulatory, capable of light work (vs. fully active) |
0.945 (0.318) | - 1 | 0.003 † |
| Baseline performance status * Time (months) | −0.029 (0.014) | - 1 | 0.043 |
| Baseline clinical stage: IIIB (vs. IIB/IIIA) | 0.115 (0.176) | 1.12 (0.80, 1.58) | 0.511 |
| Radiation dose (Gy): continuous | −0.025 (0.010) | 0.98 (0.96, 0.99) | 0.011 † |
| Chemotherapy regimen: Cisplatin + Etoposide (vs. Carboplatin + Paclitaxel) |
−0.027 (0.261) | 0.97 (0.58, 1.62) | 0.916 |
| Chemotherapy regimen: Other (vs. Carboplatin + Paclitaxel) | 0.126 (0.187) | 1.13 (0.79, 1.64) | 0.501 |
| Pre-treatment SUVpeak: continuous | −0.003 (0.011) | 0.997 (0.98, 1.02) | 0.766 |
| Pre-treatment number of hypermetabolic lesions: continuous | 0.131 (0.059) | - 1 | 0.026 |
| Pre-treatment number of hypermetabolic lesions * Time (months) | −0.006 (0.004) | - 1 | 0.074 |
| tMTV-pre: continuous 2 | 0.033 (0.008) | 1.03 (1.02, 1.05) | <0.001 † |
1
A single hazard ratio is not reported as the specified covariate is time-varying, thus implying that the hazard ratio decreases over time.
2
The reported hazard ratio corresponds to a 10mL increase in tMTV-pre.
†
P-value is below the statistical significance threshold of 0.017 (adjusted for multiple comparisons).
Abbreviations: SE=standard error; CI=confidence interval; tMTV-pre=pre-treatment total MTV